Clinical status of potential drugs used for COVID-19 treatment and recent advances in new therapeutics - A review

被引:0
作者
Mandal, Kalpa [1 ]
Singh, Meenakshi [2 ]
Chandra, Charu [1 ]
Kumawat, Indraj [1 ]
机构
[1] Univ Delhi, Dyal Singh Coll, Dept Chem, Lodhi Rd, Delhi, India
[2] Galgotias Univ, Dept Chem, Greater Noida, UP, India
来源
CHEMICAL BIOLOGY LETTERS | 2021年 / 8卷 / 03期
关键词
COVID-19; SARS-; CoV-2; Drugs; clinical trials; 2-DG; ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; SARS; REPLICATION; DISEASE; 2-DEOXY-D-GLUCOSE; IDENTIFICATION; IVERMECTIN; INFECTION; INHIBIT;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
COVID-19, a perilous disease caused by SARS-CoV-2, has brought a massive damage to humankind, and turned into a global catastrophe. It was first reported in Wuhan, China in December 2019 and since then has been a constant source of worry for the scientists and the medical world, due to the carnage it has caused globally. Extensive clinical studies are being carried to explore drug therapy and prophylaxis to combat this pestilence. It is still an excessively big challenge for the scientists and pharmacological industry to develop potential drugs for the treatment of this deadly virus. At present though no specific drug has been identified as a perfect cure for this zoonotic disease, medical practitioners are using the therapy of repurposing of drugs for the treatment. Systemic research was carried out through e-resources to identify drugs for the treatment of COVID-19. A recent proposal of 2-DG drug as a cure for COVID-19 has also been discussed in this review.
引用
收藏
页码:117 / 128
页数:12
相关论文
共 50 条
  • [31] Potential treatment of COVID-19
    Ayten, Omer
    Ozdemir, Cengiz
    Akturk, Ulku Aka
    Sen, Nazan
    [J]. EURASIAN JOURNAL OF PULMONOLOGY, 2020, 22 (04) : 35 - 44
  • [32] Recent advances in antibody-based immunotherapy strategies for COVID-19
    Esmaeilzadeh, Abdolreza
    Rostami, Samaneh
    Yeganeh, Pegah M.
    Tahmasebi, Safa
    Ahmadi, Majid
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2021, 122 (10) : 1389 - 1412
  • [33] COVID-19 Treatment-Current Status, Advances, and Gap
    Ho, Chian
    Lee, Ping-Chin
    [J]. PATHOGENS, 2022, 11 (10):
  • [34] A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence
    Ferreira-da-Silva, Renato
    Ribeiro-Vaz, Ines
    Morato, Manuela
    Polonia, Jorge Junqueira
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2022, 52 (07)
  • [35] Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
    De, Priyasha
    Chakraborty, Ishita
    Karna, Bhargavi
    Mazumder, Nirmal
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 898
  • [36] Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review
    Tsioulos, Georgios
    Grigoropoulos, Ioannis
    Moschopoulos, Charalampos D.
    Shapira, Shiran
    Poulakou, Garyfallia
    Antoniadou, Anastasia
    Boumpas, Dimitrios
    Arber, Nadir
    Tsiodras, Sotirios
    [J]. LIFE-BASEL, 2022, 12 (10):
  • [37] Review of COVID-19 treatment
    Sadeghi, Somayeh
    Momenzadeh, Mahnaz
    Nasri, Peiman
    Nickpour, Mina
    [J]. JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2020, 9 (04) : 169 - 174
  • [38] COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics
    Amawi, Haneen
    Abu Deiab, Ghina'a I.
    Aljabali, Alaa A. A.
    Dua, Kamal
    Tambuwala, Murtaza M.
    [J]. THERAPEUTIC DELIVERY, 2020, 11 (04) : 245 - 268
  • [39] Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm
    Nadaroglu, Hayrunnisa
    [J]. DRUG METABOLISM REVIEWS, 2020, 52 (04) : 531 - 539
  • [40] The Potential of Antiviral Peptides as COVID-19 Therapeutics
    Mahendran, Arun Suria Karnan
    Lim, Yin Sze
    Fang, Chee-Mun
    Loh, Hwei-San
    Le, Cheng Foh
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11